Mediledger Consortium Completes FDA Pilot For Drug Tracking On Blockchain

MediLedger, a blockchain-based pharmaceutical consortium, said it completed and released the Final Pilot Report after running a pilot program for the U.S. Food and Drug Administration (FDA) that details the ways to use blockchain for drug tracking.

The program was initiated in 2019 to help the industry move toward meeting the 2023 requirements of the Drug Supply Chain Security Act (DSCSA), that requires the pharmaceutical industry to be able to track legal changes of ownership of pharmaceuticals in the supply chain.

The pilot program was intended to help identify and evaluate the latest and efficient process that applies drug supply chain security requirements. The companies helped create a shared permissioned blockchain network that allows real-time monitoring of products.

The MediLedger FDA Pilot Project brought together some of the world’s leading pharmaceutical manufacturers, wholesale distributors, pharmaceutical dispensers, logistics companies, professional organizations, and standards bodies to explore the potential of blockchain technology in the track and trace of prescription medicines.

The 25 member consortium includes Genentech, Abbvie, Amgen, Pfizer, McKesson, Cardinal Health, Center for Supply Chain Studies, Chronicled, Dermira, Endo, FedEx, FFF Enterprises, Gilead, GS1, GSK, Hikma, Inmar, Lilly,Maxor, Novartis, Novo Nordisk, Sanofi, Vaxserve, Walgreens, Walmart and AmerisourceBergen.

The MediLedger Pilot was an exploration of the feasibility of using blockchain technology to create an electronic interoperable system as required by the DSCSA that is set to go into effect in 2023 for the pharmaceutical industry.

The report shows that the blockchain-powered MediLedger Pilot Project has the capability to be the technology underlying an interoperable system for the pharmaceutical supply chain, as mandated by DSCSA.

Source: Read Full Article